source
- Bausch + Lomb and Celldex report phase 2 trial failures in atopic dermatitisBoth Bausch + Lomb and Celldex Therapeutics announced that their recent phase 2 studies did not achieve primary efficacy goals. Celldex’s anti‑KIT antibody barzolvolimab showed no statistically si…
- This week in charts: Biotech investors’ China bets are already paying offThis year, companies built around medicines from China have sped toward acquisitions or IPOs. Meanwhile, Summit is no longer the Wall Street darling it was in 2024.BioPharma Dive · 1h ago↗ source